| Project/Area Number |
22590722
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Showa University (2011-2012)
Niigata University (2010) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUDA Yasunobu 新潟大学, 医歯学系, 准教授 (40334669)
YAMAGIWA Satoshi 新潟大学, 医歯学総合病院, 助教 (10419327)
YANO Masahiko 昭和大学, 医学部, 助教 (70529693)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | 肝臓学 / 肝癌 / インターフェロン / HBV / p21 / 細胞内局在 / 発がん抑制 / 分子機序 / IFNβ / 発癌予防 / DNA修復 / 肝細胞癌 / ウイルス発癌 / DNA修復機構 / HBx遺伝子 / ATM / トランスジェニックマウス |
|---|
| Research Abstract |
The aim of this study is to clarify the molecular mechanisms of preventive effect of IFN-beta for the occurrence of hepatocellular carcinoma (HCC) and to establish the strategy of chemoprevention of HCC. We found that aberrant expression of p21, that was a known cyclin-dependent kinase (CDK) inhibitor, was a key mechanism for hepatocarcinogenesis and it’s prevention. IFN-beta shifted cytoplasmic p21, which was oncogenic, to nucleus, making them to exert original anti-proliferative function. We may explore this anti-cancer mechanism of IFN-beta in order to apply to clinical studies.
|
